JPWO2023138696A5 - - Google Patents
Info
- Publication number
- JPWO2023138696A5 JPWO2023138696A5 JP2024543941A JP2024543941A JPWO2023138696A5 JP WO2023138696 A5 JPWO2023138696 A5 JP WO2023138696A5 JP 2024543941 A JP2024543941 A JP 2024543941A JP 2024543941 A JP2024543941 A JP 2024543941A JP WO2023138696 A5 JPWO2023138696 A5 JP WO2023138696A5
- Authority
- JP
- Japan
- Prior art keywords
- hbv
- region
- amino acid
- entry
- ifn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210079582.1A CN116510021A (zh) | 2022-01-24 | 2022-01-24 | 有限化慢性乙肝的核苷（酸）类药物治疗的药物及方法 |
| PCT/CN2023/076223 WO2023138696A1 (zh) | 2022-01-24 | 2023-02-15 | 有限化慢性乙肝的核苷(酸)类药物治疗的药物及方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025503152A JP2025503152A (ja) | 2025-01-30 |
| JP2025503152A5 JP2025503152A5 (https=) | 2026-02-17 |
| JPWO2023138696A5 true JPWO2023138696A5 (https=) | 2026-02-17 |
Family
ID=87347912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543941A Pending JP2025503152A (ja) | 2022-01-24 | 2023-02-15 | 慢性ｂ型肝炎のヌクレオシド（ヌクレオチド）類薬物の治療を有限化する薬物及び方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250161335A1 (https=) |
| EP (1) | EP4470564A4 (https=) |
| JP (1) | JP2025503152A (https=) |
| CN (2) | CN116510021A (https=) |
| WO (1) | WO2023138696A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025087290A1 (zh) * | 2023-10-27 | 2025-05-01 | 苏州瑞博生物技术股份有限公司 | 一种药物组合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102675430B (zh) * | 2005-08-12 | 2014-08-27 | 上海贺普药业股份有限公司 | 乙型肝炎病毒表面l蛋白相关肽 |
| WO2009092396A1 (en) * | 2008-01-25 | 2009-07-30 | Universitätsklinikum Heidelberg | Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| CN107106686B (zh) * | 2014-10-07 | 2022-09-27 | Myr有限公司 | Hbv和hdv感染的联合治疗 |
| CN109718364A (zh) * | 2017-10-27 | 2019-05-07 | 上海贺普药业股份有限公司 | 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法 |
| CN114828852A (zh) * | 2019-12-24 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合 |
| EP3865489A1 (en) * | 2020-02-11 | 2021-08-18 | Promidis S.r.l. | Spirocyclic inhibitors of hepatitis b virus |
-
2022
- 2022-01-24 CN CN202210079582.1A patent/CN116510021A/zh active Pending
-
2023
- 2023-02-15 JP JP2024543941A patent/JP2025503152A/ja active Pending
- 2023-02-15 WO PCT/CN2023/076223 patent/WO2023138696A1/zh not_active Ceased
- 2023-02-15 CN CN202380018193.0A patent/CN118574640A/zh active Pending
- 2023-02-15 US US18/832,497 patent/US20250161335A1/en active Pending
- 2023-02-15 EP EP23743010.3A patent/EP4470564A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102599942B1 (ko) | Hbv 및 hdv 감염의 조합 치료법 | |
| CN101970464B (zh) | 乙型肝炎病毒(HBV)的疏水性修饰的preS衍生肽及它们作为HBV和HDV进入抑制剂的使用 | |
| JP2011512123A5 (https=) | ||
| WO2019076331A1 (zh) | 非酒精性脂肪性肝病的治疗药物 | |
| JP2018512428A5 (https=) | ||
| CN1533808A (zh) | 治疗冠状病毒感染和sars的组合物与方法 | |
| CN114423430A (zh) | 使用核心蛋白别构调节剂治疗hbv感染的方法 | |
| CN116568309B (zh) | 一种用于预防或治疗慢性乙型肝炎的药物组合制剂及其用途以及组合制剂试剂盒 | |
| Qing et al. | Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice | |
| JPWO2023138696A5 (https=) | ||
| WO2011140984A1 (zh) | 抗hbv的多肽、其药物组合物及应用 | |
| US20250161335A1 (en) | Drug and Method for Nucleoside (Acid) Drug Therapy of Limiting Chronic Hepatitis B | |
| CA3144319A1 (en) | Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b. | |
| KR100587944B1 (ko) | 보강제 및 ＨＢＶ 백신 성분인 Ｂ형 간염 바이러스의ｐｒｅ Ｓ단백질 | |
| MXPA06014581A (es) | Metodo para mejorar la respuesta inmune a una vacuna. | |
| JP2009515933A (ja) | インフルエンザにおけるインターフェロン | |
| HK40088755A (zh) | Hbv和hdv感染的联合治疗 | |
| HK40083480A (en) | Combination therapy of hbv and hdv infection | |
| HK40067635A (en) | Method of treating hbv infection using a core protein allosteric modulator | |
| KR101736870B1 (ko) | 인터페론 접합체를 포함하는 복합체 및 이의 제조방법 | |
| García et al. | Factors that influence the immunogenicity of human recombinant interferon alpha-2b in mice | |
| HK40092095B (zh) | 一种用於预防或治疗慢性乙型肝炎的药物组合制剂及其用途以及组合制剂试剂盒 | |
| HK40092095A (zh) | 一种用於预防或治疗慢性乙型肝炎的药物组合制剂及其用途以及组合制剂试剂盒 | |
| EA047071B1 (ru) | Комбинированная терапия вызываемой вирусами hbv и hdv инфекции | |
| KR20170055463A (ko) | 인터페론 접합체를 포함하는 조성물 및 이의 제조방법 |